Investigational Plasma Kallikrein Inhibitors for the Treatment of Diabetic Macular Edema: an Expert Assessment

Overview

Journal Expert Opin Investig Drugs

Specialty Pharmacology

Date 2020 Jan 28

PMID 31985300

Citations 10

Authors

Ashay D Bhatwadekar

Viral S Kansara

Thomas A Ciulla

Affiliations

Soon will be listed here.

Abstract

: Plasma kallikrein is a mediator of vascular leakage and inflammation. Activation of plasma kallikrein can induce features of diabetic macular edema (DME) in preclinical models. Human vitreous shows elevated plasma kallikrein levels in patients with DME. Because of the incomplete response of some patients to anti-VEGF agents, and the treatment burden associated with frequent dosing, there is still considerable need for VEGF-independent targeted pathways.: This review covers the role of plasma kallikrein in the pathogenesis of DME and the therapeutic potential of plasma kallikrein inhibitors. It discusses early clinical studies of plasma kallikrein pathway modulation for DME, which have been associated with some improvement in visual acuity but with limited improvement in macular edema. This review also highlights KVD001, which is furthest along the development pathway, THR-149, which has recently completed a phase 1 study, and oral agents under development.: Plasma kallikrein inhibitors have a potential role in the treatment of DME, with mixed functional/anatomic results in early clinical trials. Given the large unmet need in DME treatment, further studies are warranted.

Citing Articles

Diabetic macular edema (DME): dissecting pathogenesis, prognostication, diagnostic modalities along with current and futuristic therapeutic insights.

Al Sakini A, Hamid A, Alkhuzaie Z, Al-Aish S, Al-Zubaidi S, Tayem A Int J Retina Vitreous. 2024; 10(1):83.

PMID: 39468614 PMC: 11514910. DOI: 10.1186/s40942-024-00603-y.

A novel assay of excess plasma kallikrein-kinin system activation in hereditary angioedema.

Sexton D, Faucette R, Rivera-Hernandez M, Kenniston J, Papaioannou N, Cosic J Front Allergy. 2024; 5:1436855.

PMID: 39391687 PMC: 11464748. DOI: 10.3389/falgy.2024.1436855.

Human plasma kallikrein: roles in coagulation, fibrinolysis, inflammation pathways, and beyond.

Motta G, Juliano L, Chagas J Front Physiol. 2023; 14:1188816.

PMID: 37711466 PMC: 10499198. DOI: 10.3389/fphys.2023.1188816.

Plasma Kallikrein Inhibitors as Potential Treatment for Diabetic Macular Edema, Retinal Vein Occlusion, Hereditary Angioedema and Other Related Diseases.

Abdel-Magid A ACS Med Chem Lett. 2023; 14(2):129-130.

PMID: 36793429 PMC: 9923826. DOI: 10.1021/acsmedchemlett.2c00526.

Current and Novel Therapeutic Approaches for Treatment of Diabetic Macular Edema.

Chauhan M, Rather P, Samarah S, Elhusseiny A, Sallam A Cells. 2022; 11(12).

PMID: 35741079 PMC: 9221813. DOI: 10.3390/cells11121950.

References

Liu J, Feener E . Plasma kallikrein-kinin system and diabetic retinopathy. Biol Chem. 2013; 394(3):319-28. PMC: 4844060. DOI: 10.1515/hsz-2012-0316. View

Kaschina E, Stoll M, Sommerfeld M, Steckelings U, Kreutz R, Unger T . Genetic kininogen deficiency contributes to aortic aneurysm formation but not to atherosclerosis. Physiol Genomics. 2004; 19(1):41-9. DOI: 10.1152/physiolgenomics.00035.2004. View

Zur D, Iglicki M, Loewenstein A . The Role of Steroids in the Management of Diabetic Macular Edema. Ophthalmic Res. 2019; 62(4):231-236. DOI: 10.1159/000499540. View

Lawson S, Gabra B, Guerin B, Neugebauer W, Nantel F, Battistini B . Enhanced dermal and retinal vascular permeability in streptozotocin-induced type 1 diabetes in Wistar rats: blockade with a selective bradykinin B1 receptor antagonist. Regul Pept. 2004; 124(1-3):221-4. DOI: 10.1016/j.regpep.2004.09.002. View

Kita T, Clermont A, Murugesan N, Zhou Q, Fujisawa K, Ishibashi T . Plasma Kallikrein-Kinin System as a VEGF-Independent Mediator of Diabetic Macular Edema. Diabetes. 2015; 64(10):3588-99. PMC: 4587649. DOI: 10.2337/db15-0317. View

Wells J, Glassman A, Ayala A, Jampol L, Bressler N, Bressler S . Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-Year Results from a Comparative Effectiveness Randomized Clinical Trial. Ophthalmology. 2016; 123(6):1351-9. PMC: 4877252. DOI: 10.1016/j.ophtha.2016.02.022. View

Morello C . Etiology and natural history of diabetic retinopathy: an overview. Am J Health Syst Pharm. 2007; 64(17 Suppl 12):S3-7. DOI: 10.2146/ajhp070330. View

Ciulla T, Amador A, Zinman B . Diabetic retinopathy and diabetic macular edema: pathophysiology, screening, and novel therapies. Diabetes Care. 2003; 26(9):2653-64. DOI: 10.2337/diacare.26.9.2653. View

Clermont A, Chilcote T, Kita T, Liu J, Riva P, Sinha S . Plasma kallikrein mediates retinal vascular dysfunction and induces retinal thickening in diabetic rats. Diabetes. 2011; 60(5):1590-8. PMC: 3292335. DOI: 10.2337/db10-1260. View

10.

Dugel P, Layton A, Varma R . Diabetic Macular Edema Diagnosis and Treatment in the Real World: An Analysis of Medicare Claims Data (2008 to 2010). Ophthalmic Surg Lasers Imaging Retina. 2016; 47(3):258-67. DOI: 10.3928/23258160-20160229-09. View

11.

Emanueli C, Salis M, Stacca T, Pintus G, Kirchmair R, Isner J . Targeting kinin B(1) receptor for therapeutic neovascularization. Circulation. 2002; 105(3):360-6. DOI: 10.1161/hc0302.102142. View

12.

Blinder K, Dugel P, Chen S, Jumper J, Walt J, Hollander D . Anti-VEGF treatment of diabetic macular edema in clinical practice: effectiveness and patterns of use (ECHO Study Report 1). Clin Ophthalmol. 2017; 11:393-401. PMC: 5328320. DOI: 10.2147/OPTH.S128509. View

13.

Sahni J, Patel S, Dugel P, Khanani A, Jhaveri C, Wykoff C . Simultaneous Inhibition of Angiopoietin-2 and Vascular Endothelial Growth Factor-A with Faricimab in Diabetic Macular Edema: BOULEVARD Phase 2 Randomized Trial. Ophthalmology. 2019; 126(8):1155-1170. DOI: 10.1016/j.ophtha.2019.03.023. View

14.

Clermont A, Murugesan N, Zhou Q, Kita T, Robson P, Rushbrooke L . Plasma Kallikrein Mediates Vascular Endothelial Growth Factor-Induced Retinal Dysfunction and Thickening. Invest Ophthalmol Vis Sci. 2016; 57(6):2390-9. PMC: 4857835. DOI: 10.1167/iovs.15-18272. View

15.

Phipps J, Clermont A, Sinha S, Chilcote T, Bursell S, Feener E . Plasma kallikrein mediates angiotensin II type 1 receptor-stimulated retinal vascular permeability. Hypertension. 2009; 53(2):175-81. PMC: 4978181. DOI: 10.1161/HYPERTENSIONAHA.108.117663. View

16.

Parenti A, Morbidelli L, Ledda F, Granger H, Ziche M . The bradykinin/B1 receptor promotes angiogenesis by up-regulation of endogenous FGF-2 in endothelium via the nitric oxide synthase pathway. FASEB J. 2001; 15(8):1487-9. View

17.

Ferris 3rd F, Patz A . Macular edema. A complication of diabetic retinopathy. Surv Ophthalmol. 1984; 28 Suppl:452-61. DOI: 10.1016/0039-6257(84)90227-3. View

18.

Ciulla T, Harris A, Latkany P, Piper H, Arend O, Garzozi H . Ocular perfusion abnormalities in diabetes. Acta Ophthalmol Scand. 2002; 80(5):468-77. DOI: 10.1034/j.1600-0420.2002.800503.x. View

19.

Hussain R, Ciulla T . Treatment strategies for refractory diabetic macular edema: switching anti-VEGF treatments, adopting corticosteroid-based treatments, and combination therapy. Expert Opin Biol Ther. 2015; 16(3):365-74. DOI: 10.1517/14712598.2016.1131265. View

20.

Murugesan N, Fickweiler W, Clermont A, Zhou Q, Feener E . Retinal proteome associated with bradykinin-induced edema. Exp Eye Res. 2019; 186:107744. DOI: 10.1016/j.exer.2019.107744. View